In the dynamic realm of clinical development, where cutting-edge drugs and therapies emerge, there is a glaring issue: the significant underrepresentation of diversity among clinical trial participants. It's akin to hosting a grand fiesta with only a fraction of the invitees in attendance. However, let's transform this landscape! Let's work together to foster a more inclusive and vibrant environment than ever before. The Usual Suspects: Why Diversity Matters Picture a clinical trial. If you're imagining a room full of Caucasian males, you're not far off the mark. This homogeneity is more than just dull; it's problematic. It's like testing a one-size-fits-all suit on a single body type and hoping it fits the rest of the world. We need to know how treatments work across all demographics, not just a select few. A Fresh Perspective: Let’s Shake Things Up As a member of the clinical development team and a proud first-gen Latina, I've made it my mission to add color and variety to this picture. Even though I have not been able to achieve this for all studies this year, I am hoping to continue to make advances to a more diverse patient population for our clinical studies. Here are some things we can all work on ● Championing Diversity: We can all advocate for diversity and inclusion throughout every phase of clinical trial planning and execution. This encompasses everything from collaborating with colleagues on designing inclusive trial protocols that encourage participation from underrepresented groups to ensure that the entire team aligns with the overarching goal of health equity. It's about integrating diversity into the very fabric of our projects, making it a fundamental aspect of our approach rather than an afterthought. ● Culturally Competent Clinical Teams: From data management and clinical operations to the regulatory team… clinical trial teams should not be just scientifically sharp; they should be culturally tuned in about being as flu
Supplements
Digestive enzymes play an essential role in breaking down food and enabling the body to absorb the nutrients needed to sustain health. For patients whose pancreas cannot produce enough digestive enzymes, such as many people living with cystic fibrosis and pancreatic cancer, pancreatic enzyme replacement therapy (PERT) becomes a medical necessity. Without adequate enzyme replacement, some patients may be forced to reduce food intake because they cannot properly digest meals. Yet, only a small number of manufacturers produce these therapies and relatively few suppliers serve patients across North America and other international markets. This scarcity reflects the limited availability of pancrelipase active pharmaceutical ingredients (APIs), the highly specialized expertise required to manufacture these complex formulations, and the significant technical barriers to expanding production. Drawing on more than 30 years of expertise, PanCap Pharma has built specialized capabilities in pancreatic enzyme replacement therapies to overcome these challenges. Protecting pancreatic enzymes until they reach the small intestine is one of the most technically demanding aspects of enzyme replacement therapy. Exposure to stomach acid can significantly reduce enzyme activity before digestion even begins, making the delivery system just as important as the enzymes themselves..
Pharmaceutical Packaging
Every sample, whether a cryotube or microscope slide, carries critical data and the potential to drive breakthrough discoveries. Safeguarding that data’s integrity remains an ongoing challenge for laboratories. Labels are essential for ensuring samples remain identifiable and traceable, even under extreme conditions such as cryogenic storage, exposure to harsh chemicals, or steam sterilization in an autoclave. A single misidentification can derail a clinical trial, trigger compliance issues, or delay vital research. This challenge is the driving force behind GA International. As a pioneering leader in advanced identification technologies, the company has made sample integrity its mission. Through its life sciences brand, LabTAG, it delivers end-to-end identification solutions tailored to biomedical research, manufacturing, and clinical workflows. By integrating hardware, software, and technical expertise, LabTAG provides a dependable framework for data accuracy and compliance. From bench to bedside, it protects the process, ensuring discoveries advance and patient safety is never compromised. “Our goal is to help the scientific community have more efficient sample management solutions,” says George Ambartsoumian, CEO and president. Recognizing that every lab has unique needs, LabTAG provides customized labeling solutions designed to withstand the toughest laboratory conditions. Its portfolio includes cryogenic labels that endure ultra-low temperatures in liquid nitrogen, chemical-resistant labels that hold up against harsh solvents, tissue fixing and staining in histology, and autoclave labels that endure steam sterilization. Together, these solutions ensure sample identification remains reliable and traceable at every stage of research. .
Clinical Laboratory Services
Omnitech Labs is a pioneer in laboratory information systems (LIS) and offers one of the longest-standing LIS platforms on the market. Its flagship solution, OMNI-Lab, is a fully integrated LIS suite known for its reliability and efficiency, making it a dependable partner for laboratories. Designed for public and private laboratories, Omnitech Labs empowers clients of every size, from small facilities and regional networks to some of Canada’s largest lab groups and high-volume veterinary laboratories. It manages the full spectrum of lab operations, from physician test requisitions and draw center logistics to processing, and reporting. “We bring efficiency and productivity to clients through a solution that delivers sustainable value,” says Andre St-Jean, president and CEO. In environments where downtime is not an option, OMNI-Lab sets the standard with a guaranteed availability rate of 99.995. Its robust design is supported by a resilient infrastructure and continuous, web-based monitoring, ensuring that mission-critical laboratories remain fully operational. With OMNI-Lab, laboratories can boost efficiency by up to 500 percent. Its intuitive workflow streamlines operations, reduces repetitive tasks and transforms the investment into a self-funded project that delivers substantial savings and reliable results. Efficiency gains extend to laboratory staff and management. Automated processes and real-time analytics reduce administrative burden while freeing experts to focus on complex tasks requiring human expertise. Approved for sale in Canada and the U.S., OMNILab operates under an ISO 13485:2016 certified quality management system, ensuring reliability and compliance for even the most complex laboratory workflows. .
Drug Discovery and Development
Accelerating Early-Stage Drug Development
Safwan Kezbor, M.D., Executive Medical Director, Global Clinical Development, Shionogi Inc
Clinical Trial
The Role of Statisticians in Study Design and Why to Engage Them Early
Melanie Buitendyk, Vice President Biostatistics and Statistical Programming, Allucent
CRO
The Laboratory's Central Role in Patient Management
Allen C. Omo-Ogboi, MD, Laboratory Medical Director, Pikeville Medical Center
IN MY OPINION
Life Science Consulting
Enhancing HCP Engagement by Evolving our Medical DNA
Sebastien Michaud, Vice President, Medical Strategy Oncology & Neurology / Immunology, North America Medical Affairs, EMD Serono, Inc
LAST WORD
Life Science Consulting
Why a Quality Mindset Must Drive IT Change in Life Sciences
Paul Rascoe, Sr. Manager, IT SAP Systems, Beam Therapeutics
IN FOCUS
Advancing Antibacterial Treatment Strategies for Better Infection Control in Canada
Antibacterial treatments help control infections through targeted therapies, accurate diagnosis, preventive care, and evidence-based healthcare practices.
Pancreatic Enzyme Manufacturers Are Advancing Digestive Health Solutions in Canada
Canadian pancreatic enzyme manufacturers are advancing personalized digestive therapies through biotechnology, sustainability, digital healthcare innovation and improved patient-focused treatment solutions.
EDITORIAL
Advancing Life Sciences through Precision and Purpose
Our cover story features Recordati, highlighting its continued focus on rare diseases and the communities affected by them. Through Recordati Rare Diseases Canada, the company works across genetic metabolic disorders, rare endocrinology conditions and other specialized therapeutic areas while supporting awareness, education and advocacy efforts. Its approach reflects a commitment to developing and improving access to therapies for patient populations that often face significant diagnostic and treatment challenges.
Also featured is Pancap Pharma, recognized as the Top Pancreatic Digestive Enzyme Manufacturers in Canada 2026. Drawing on more than 30 years of expertise, Pancap has developed specialized capabilities in pancreatic enzyme replacement therapies through advanced entericcoating technology, specialized manufacturing processes and expanded production capacity. Its Windsor facility strengthens its ability to support digestive health solutions and improve access to enzyme therapies.
The issue also features perspectives from leaders shaping the future of life sciences. Sébastien Michaud, VP, Medical Strategy Oncology & Neurology / Immunology, North America Medical Affairs at EMD Serono, Inc., discusses how Medical Affairs is evolving through personalized medicine, data-driven engagement and stronger connections with healthcare professionals. Paul Rascoe, Sr. Manager, IT SAP Systems at Beam Therapeutics, examines why quality must guide technology decisions in life sciences, ensuring innovation supports compliance, data integrity and patient safety.
Together, these stories show how life sciences progress depends on combining scientific expertise with patient-focused decisions. We invite our readers to explore these perspectives and discover how innovation, quality and collaboration continue to shape the future of healthcare in Canada.
